The White House has released a report projecting more than $500 billion in savings over the next decade by pegging U.S. prescription drug prices to those in other wealthy nations. This initiative, known as “Most Favored Nation” (MFN) pricing, aims to align American costs with international benchmarks. However, independent analysis suggests these figures are highly speculative, relying on implausible modeling assumptions and opaque data.
While all administrations seek to highlight policy successes, the current projections face significant scrutiny regarding their feasibility, transparency, and potential unintended consequences for patients and the pharmaceutical market.
The Two Tracks of MFN Pricing
The administration’s strategy divides into two distinct categories: retroactive pricing for existing drugs and prospective pricing for new launches. Each faces unique logistical and economic hurdles.
Existing Drugs and the TrumpRx Platform
For medications already on the market, the White House estimates $64 billion in federal and state savings over ten years. This relies on voluntary agreements between drug manufacturers and the government, setting prices based on the “second-lowest” rates among nine comparable wealthy nations.
A key component of this track is TrumpRx.gov, a direct-to-consumer platform launched in February. The administration claims it offers world-low prices for uninsured patients. However, critics point out several structural limitations:
- Limited Impact on Generics: Most drugs available on TrumpRx are in the late stages of their product lifecycle, meaning they already face competition from cheaper generic or biosimilar alternatives. Other platforms, such as Cost Plus Drugs and GoodRx, often provide deeper discounts for these same products.
- Irrelevance for Insured Patients: For individuals with insurance, co-payments are typically lower than the cash discounts offered by TrumpRx.
- The Deductible Trap: Purchases made outside of insurance (cash-pay) generally do not count toward insurance deductibles or out-of-pocket maximums. This leaves patients financially exposed, as they must still pay full price for other medications until their insurance coverage kicks in.
While proposed legislation aims to count these purchases toward deductibles, insurers would likely respond by raising premiums to offset the added liability, potentially negating patient savings.
New Drug Launches and Global Price Convergence
The bulk of the projected savings—$529 billion —comes from prospective MFN pricing for new drugs. The administration asserts that manufacturers will price new U.S. launches comparably to other high-income countries, aiming for a 30% reduction in U.S. prices while assuming international prices will rise.
This model relies on the concept of “price equalization,” which economists argue is flawed. There is no “law of one price” for pharmaceuticals; costs vary significantly across countries due to different regulatory environments, negotiation powers, and healthcare systems. Furthermore, the assumption that other developed nations will raise their drug prices contradicts current trends, where many countries are tightening budgets and driving prices down.
Critical Flaws in the Model
The feasibility of the MFN framework is undermined by several practical and regulatory realities:
- Data Opacity: MFN calculations require access to international net prices (prices after rebates and discounts). However, many comparator nations, including France, have laws explicitly forbidding the public release of net prices. Without this data, verifying whether U.S. prices are actually lower is impossible.
- Regulatory Timing Mismatches: The model assumes new drugs are approved simultaneously in the U.S. and comparator nations. In reality, over 70% of drugs are approved in the U.S. first. With five different regulatory agencies among comparator countries, approval timelines vary widely. If a drug is not yet approved abroad, there is no international price to benchmark against.
- Market Withdrawal Risk: Pharmaceutical companies may choose not to launch drugs in certain jurisdictions to avoid MFN pricing constraints. This could limit patient access to new therapies in the very countries the policy aims to help.
- Lack of Independent Verification: The White House has not disclosed the terms of its agreements with manufacturers, citing concerns about moving financial markets. Consequently, no independent body can verify the projected savings.
Corporate Response and Profitability Concerns
A growing critique of the MFN deals is that pharmaceutical companies do not appear to view them as a significant threat to their bottom lines. Public Citizen noted that in shareholder communications, drug corporations have not indicated anticipating major impacts from these agreements.
This raises questions about the substance of the deals. Are the price cuts minimal? Are there hidden offsets in the contracts? Or do companies expect increased patient utilization to offset lower prices?
An April analysis by staff for Sen. Bernie Sanders (I-Vt.) examined 15 companies involved in MFN deals and found their combined profits rose 66% over the past year. The report also highlighted that recent tax legislation exempted many expensive drugs, such as the cancer therapy Keytruda, from Medicare price negotiations, providing a financial reprieve that may offset any MFN-related revenue losses.
The Trump administration countered that the Sanders analysis was flawed because it relied on list prices rather than net prices, arguing it overstated profit estimates.
Conclusion
The White House’s MFN drug pricing initiative presents an ambitious goal: lowering U.S. drug costs by aligning them with international standards. However, the $500 billion savings projection rests on unverifiable data, unrealistic assumptions about global price convergence, and complex logistical barriers. Without transparent agreement terms and independent verification, it remains unclear whether this framework will deliver meaningful relief to patients or simply reshape the financial dynamics of the pharmaceutical industry without significant net savings.
